Adalimumab induced subcutaneous nodular sarcoidosis; A rare side effect of tumor necrosis Factor-α Inhibitor

Sonoa Au, Mehdi Mirsaeidi, Iris K. Aronson, Nadera J. Sweiss

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Adalimumab and other tumor necrosis factor-α inhibitors have been shown in the recent years to successfully treat sarcoidosis refractory to systemic corticosteroids and other agents. However, there have been an increasing number of cases of sarcoidosis paradoxically induced by these agents. It is hypothesized that this is due to the disruption of the fine balance of cytokines involved in granuloma formation.We describe the first case of adalimumab-induced subcutaneous nodular sarcoidosis in a patient with pulmonary sarcoidosis.

Original languageEnglish (US)
Pages (from-to)249-251
Number of pages3
JournalSarcoidosis Vasculitis and Diffuse Lung Diseases
Volume31
Issue number3
StatePublished - 2014
Externally publishedYes

Fingerprint

Sarcoidosis
Tumor Necrosis Factor-alpha
Pulmonary Sarcoidosis
Granuloma
Adrenal Cortex Hormones
Cytokines
Adalimumab

Keywords

  • Adalimumab
  • Anti-TNF-α antibody
  • Pulmonary sarcoidosis
  • Subcutaneous nodular sarcoidosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Internal Medicine

Cite this

Adalimumab induced subcutaneous nodular sarcoidosis; A rare side effect of tumor necrosis Factor-α Inhibitor. / Au, Sonoa; Mirsaeidi, Mehdi; Aronson, Iris K.; Sweiss, Nadera J.

In: Sarcoidosis Vasculitis and Diffuse Lung Diseases, Vol. 31, No. 3, 2014, p. 249-251.

Research output: Contribution to journalArticle

@article{132dbcdf67ad46b2bf597053180de15f,
title = "Adalimumab induced subcutaneous nodular sarcoidosis; A rare side effect of tumor necrosis Factor-α Inhibitor",
abstract = "Adalimumab and other tumor necrosis factor-α inhibitors have been shown in the recent years to successfully treat sarcoidosis refractory to systemic corticosteroids and other agents. However, there have been an increasing number of cases of sarcoidosis paradoxically induced by these agents. It is hypothesized that this is due to the disruption of the fine balance of cytokines involved in granuloma formation.We describe the first case of adalimumab-induced subcutaneous nodular sarcoidosis in a patient with pulmonary sarcoidosis.",
keywords = "Adalimumab, Anti-TNF-α antibody, Pulmonary sarcoidosis, Subcutaneous nodular sarcoidosis",
author = "Sonoa Au and Mehdi Mirsaeidi and Aronson, {Iris K.} and Sweiss, {Nadera J.}",
year = "2014",
language = "English (US)",
volume = "31",
pages = "249--251",
journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",
issn = "1124-0490",
publisher = "Mattioli 1885 S.p.A.",
number = "3",

}

TY - JOUR

T1 - Adalimumab induced subcutaneous nodular sarcoidosis; A rare side effect of tumor necrosis Factor-α Inhibitor

AU - Au, Sonoa

AU - Mirsaeidi, Mehdi

AU - Aronson, Iris K.

AU - Sweiss, Nadera J.

PY - 2014

Y1 - 2014

N2 - Adalimumab and other tumor necrosis factor-α inhibitors have been shown in the recent years to successfully treat sarcoidosis refractory to systemic corticosteroids and other agents. However, there have been an increasing number of cases of sarcoidosis paradoxically induced by these agents. It is hypothesized that this is due to the disruption of the fine balance of cytokines involved in granuloma formation.We describe the first case of adalimumab-induced subcutaneous nodular sarcoidosis in a patient with pulmonary sarcoidosis.

AB - Adalimumab and other tumor necrosis factor-α inhibitors have been shown in the recent years to successfully treat sarcoidosis refractory to systemic corticosteroids and other agents. However, there have been an increasing number of cases of sarcoidosis paradoxically induced by these agents. It is hypothesized that this is due to the disruption of the fine balance of cytokines involved in granuloma formation.We describe the first case of adalimumab-induced subcutaneous nodular sarcoidosis in a patient with pulmonary sarcoidosis.

KW - Adalimumab

KW - Anti-TNF-α antibody

KW - Pulmonary sarcoidosis

KW - Subcutaneous nodular sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=84948953648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948953648&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 249

EP - 251

JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases

JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases

SN - 1124-0490

IS - 3

ER -